We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+12.76%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$2.18B
AUM Growth
-$420M
Cap. Flow
-$342M
Cap. Flow %
-15.71%
Top 10 Hldgs %
69.34%
Holding
52
New
10
Increased
7
Reduced
16
Closed
7

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$19.8M
2
AMRN
Amarin Corp
AMRN
+$15.3M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$13.5M
4
ESTA icon
Establishment Labs
ESTA
+$12.2M
5
YMAB
Y-mAbs Therapeutics
YMAB
+$7.88M

Top Sells

Rank Stock Value
1
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$71.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$69M
3
PTCT icon
PTC Therapeutics
PTCT
+$66.7M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$48.4M
5
PCRX icon
Pacira BioSciences
PCRX
+$45.3M

Sector Composition

Rank Sector Weight
1 Healthcare 82.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$369M 16.94%
17,714,461
– –
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$226M 10.38%
4,798,101
– –
SRPT icon
3
Sarepta Therapeutics
SRPT
$1.64B
$152M 7%
943,500
-15,428
-2% -$2.11M
ASND icon
4
Ascendis Pharma A/S
ASND
$16.5B
$139M 6.39%
1,963,336
-100,000
-5% -$6.88M
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$11.9B
$133M 6.09%
1,368,103
-254,667
-16% -$25.4M
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
$113M 5.18%
9,333,132
-36,018
-0.4% -$504K
MDGL icon
7
Madrigal Pharmaceuticals
MDGL
$12.6B
$99.1M 4.55%
463,000
-26,536
-5% -$6.66M
IOVA icon
8
Iovance Biotherapeutics
IOVA
$2.04B
$97.5M 4.48%
8,662,720
+485,000
+6% +$6.88M
ECYT
9
DELISTED
Endocyte, Inc. Common Stock
ECYT
$94.2M 4.32%
5,301,718
-393,482
-7% -$6.76M
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$87.3M 4.01%
4,460,426
-1,133,257
-20% -$21.5M
ZGNX
11
DELISTED
Zogenix, Inc.
ZGNX
$72.3M 3.32%
1,457,913
-45,400
-3% -$2.31M
AMRN
12
Amarin Corp
AMRN
$297M
$65.8M 3.02%
+202,250
New +$15.3M
ARGX icon
13
argenx
ARGX
$55.2B
$57.3M 2.63%
755,415
-26,638
-3% -$2.36M
TCDA
14
DELISTED
Tricida, Inc. Common Stock
TCDA
$54.1M 2.49%
1,771,500
+675,736
+62% +$19.8M
PBYI icon
15
Puma Biotechnology
PBYI
$398M
$52.8M 2.42%
1,150,685
+116,310
+11% +$5.61M
ASMB icon
16
Assembly Biosciences
ASMB
$498M
$38.9M 1.79%
87,369
+7,083
+9% +$3.32M
CLVS
17
DELISTED
Clovis Oncology, Inc.
CLVS
$33.7M 1.55%
1,146,636
+200
+0% +$7.74K
PTCT icon
18
PTC Therapeutics
PTCT
$6.18B
$32.1M 1.48%
684,000
-1,610,877
-70% -$66.7M
XENE icon
19
Xenon Pharmaceuticals
XENE
$6.1B
$31.2M 1.43%
2,367,218
+1,165,100
+97% +$13.5M
TGTX icon
20
TG Therapeutics
TGTX
$8.19B
$23.5M 1.08%
4,200,031
-750,000
-15% -$8.57M
TLGT
21
DELISTED
Teligent, Inc
TLGT
$20.9M 0.96%
529,943
– –
PCRX icon
22
Pacira BioSciences
PCRX
$1.04B
$20.3M 0.93%
413,196
-1,047,414
-72% -$45.3M
CPRX
23
DELISTED
Catalyst Pharmaceutical
CPRX
$17M 0.78%
4,497,042
– –
ARWR icon
24
Arrowhead Research
ARWR
$12.1B
$16.3M 0.75%
849,899
+399,899
+89% +$6.56M
BDSI
25
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$15.2M 0.7%
5,437,779
– –
1
2 3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q3 2018 Portfolio in Review

As of Q3 2018, Avoro Capital Advisors held 52 positions worth $2.18B, down 16% from $2.6B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Avoro Capital Advisors withdrew a net $342M in Q3 2018, closing 7 positions and reducing 16 holdings. Its most notable exit was Spectrum Pharmaceuticals Inc, an estimated $71.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 82% a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in Amarin Corp worth $65.8M.

  • Avoro Capital Advisors's largest Q3 2018 buy was Amarin Corp: 202,250 shares worth $65.8M.
  • Avoro Capital Advisors added most to Tricida, Inc. Common Stock in Q3 2018, an estimated $19.8M increase.
  • Avoro Capital Advisors's biggest Q3 2018 reduction was PTC Therapeutics, cutting an estimated $66.7M.
  • Avoro Capital Advisors fully exited Spectrum Pharmaceuticals Inc in Q3 2018, selling an estimated $71.7M.
  • Avoro Capital Advisors's ten largest holdings make up 69% of its $2.18B portfolio in Q3 2018.
  • Avoro Capital Advisors opened 10 new positions and closed 7 in Q3 2018.
  • Avoro Capital Advisors's portfolio value fell 16% quarter-over-quarter to $2.18B.

Based on Avoro Capital Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.